China's securities regulator has fined Tiger Brokers and Futu Securities for illegally offering mainland investors access to overseas trading. The CSRC stated the companies promoted trading and handled orders without approval, disrupting market order and threatening financial stability. Hong Kong's SFC also increased scrutiny.
China's securities regulator has fined Tiger Brokers and Futu Securities for illegally providing mainland investors access to overseas stock trading. The CSRC stated the companies disrupted market order and will confiscate ill-gotten gains.
China's CSRC is investigating Tiger Brokers, Futu Securities, and Changqiao Securities for illegally operating securities businesses in mainland China without approval, including marketing, processing trades, and selling public funds. Penalties may include confiscation of illegal gains.
YMTC, China's leading 3D NAND flash memory manufacturer, is preparing for an IPO. Its parent company has begun the official tutoring process with Citic Securities and China Securities, signaling a push for capital market involvement in the nation's semiconductor self-reliance efforts.
The parent company of Yangtze Memory Technologies Co, China's leading 3D NAND flash memory manufacturer, has officially begun the tutoring process for an initial public offering, according to a regulatory filing.
A former head of China’s equities market regulator will face trial on allegations that he took vast sums in bribes in return for approving company listings and loans, according to the Communist Party’s top anti-graft watchdog. Yi Huiman, former chairman of the China Securities Regulatory Commission (CSRC), allegedly used “his position to seek benefits for others in job promotions, listing approvals and obtaining loans, and illegally accepted huge amounts of bribes”, the Central Commission for...
Eight mainland China-based companies, including five biotech firms, passed listing hearings on the Hong Kong stock market in April. Metis, founded in 2020 in Hangzhou, uses three proprietary AI platforms to design drug delivery systems. Its revenue surged to 105 million yuan in 2025 from 1.48 million yuan in 2024, while net loss narrowed to 391.8 million yuan. Its leading drug candidate MTS-004 for pseudobulbar affect has completed phase three trials.
